中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Viral Diseases
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
Investors
Financials & Filing
2025
2024
2023
2022
2021
2020
2019
2018
2025
2024
2023
2022
2021
2020
2019
2018
Notice of Board Meeting
2025-03-13
Inside Information - Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
2025-03-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
2025-03-05
Inside Information - Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
2025-02-19
Next Day Disclosure Return
2025-02-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-02-05
Poll Results of the Extraordinary General Meeting Held on February 3, 2025
2025-02-03
Next Day Disclosure Returns - Share Buyback
2025-01-24
Next Day Disclosure Returns - Share Buyback
2025-01-23
Voluntary Announcement - Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
2025-01-21
1
2
3
»